Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
About this item
Full title
Author / Creator
Zeiser, Robert , Polverelli, Nicola , Ram, Ron , Hashmi, Shahrukh K , Chakraverty, Ronjon , Middeke, Jan Moritz , Musso, Maurizio , Giebel, Sebastian , Uzay, Ant , Langmuir, Peter , Hollaender, Norbert , Gowda, Maanasa , Stefanelli, Tommaso , Lee, Stephanie J , Teshima, Takanori and Locatelli, Franco
Publisher
Boston: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Standard treatment for GVHD is glucocorticoids, but for glucocorticoid-refractory GVHD, no intervention has emerged as standard second-line treatment. This trial with 329 patients compared ruxolitinib with control (chosen from among 10 possible therapies) in patients with glucocorticoid-refractory chronic GVHD. Response at week 24 was 50% with ruxo...
Alternative Titles
Full title
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2552062198
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2552062198
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2033122
